Literature DB >> 7762425

Lactoferrin and the inflammatory response.

R D Baynes1, W R Bezwoda.   

Abstract

Polyclonal antibodies were prepared to purified breast milk lactoferrin and used in an ELISA to measure plasma concentrations in investigations of various aspects of the inflammatory response. They were also used, in situ, to evaluate granulocyte lactoferrin content in disease states. The first series of studies addressed the putative role of lactoferrin in the pathogenesis of the hypoferremic, hyperferritinemic response to acute inflammation. Dissociation between the lactoferrin response and the iron related changes in rheumatoid arthritis and after alpha-interferon administration suggested that the relationship observed in acute and chronic bacterial infection may reflect coincidental effects of inflammatory cytokines. That lactoferrin does not mediate the inflammatory hypoferremic response was established by the finding that bone marrow transplant recipients, post-myeloablation, developed a hypoferremic response during septic episodes despite virtually undetectable plasma lactoferrin concentrations. The second series of investigations employed the plasma lactoferrin concentration as an index of granulocyte activation and function in a number of inflammatory conditions. Markedly increased initial plasma concentrations in acute pneumonia reflecting profound intravascular granulocyte activation were documented to predict sepsis related mortality. Plasma and granulocyte lactoferrin studies established that viral infection is associated with an acquired granulocyte lactoferrin deficiency. Plasma measurements indicated that asthmatics, even when clinically asymptomatic, have evidence of persistent granulocyte activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7762425     DOI: 10.1007/978-1-4615-2548-6_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  20 in total

1.  Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.

Authors:  Takayuki Yamamoto; Manabu Shiraki; Takuya Bamba; Satoru Umegae; Koichi Matsumoto
Journal:  Int J Colorectal Dis       Date:  2013-12-17       Impact factor: 2.571

2.  Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice.

Authors:  Senthil Kumar Velusamy; Daniel H Fine; Kabilan Velliyagounder
Journal:  Microbes Infect       Date:  2014-08-11       Impact factor: 2.700

3.  Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression.

Authors:  Marian L Kruzel; Jeffrey K Actor; Michał Zimecki; Jasen Wise; Paulina Płoszaj; Shaper Mirza; Mark Kruzel; Shen-An Hwang; Xueqing Ba; Istvan Boldogh
Journal:  J Biotechnol       Date:  2013-09-23       Impact factor: 3.307

4.  Optimized lactoferrin as a highly promising treatment for intracerebral hemorrhage: Pre-clinical experience.

Authors:  Xiurong Zhao; Marian Kruzel; Shun-Ming Ting; Guanghua Sun; Sean I Savitz; Jaroslaw Aronowski
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-21       Impact factor: 6.200

5.  Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin.

Authors:  Songtao Li; Haibo Zhou; Guirong Huang; Ning Liu
Journal:  Med Microbiol Immunol       Date:  2008-09-23       Impact factor: 3.402

Review 6.  Lactoferrin as a natural immune modulator.

Authors:  Jeffrey K Actor; Shen-An Hwang; Marian L Kruzel
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 7.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

8.  Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response.

Authors:  Byung-Kwon Choi; Jeffrey K Actor; Sandra Rios; Marc d'Anjou; Terrance A Stadheim; Shannon Warburton; Erin Giaccone; Michael Cukan; Huijuan Li; Angela Kull; Nathan Sharkey; Paul Gollnick; Maja Kocieba; Jolanta Artym; Michal Zimecki; Marian L Kruzel; Stefan Wildt
Journal:  Glycoconj J       Date:  2008-03-26       Impact factor: 2.916

9.  Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study.

Authors:  Takayuki Yamamoto; Manabu Shiraki; Takuya Bamba; Satoru Umegae; Koichi Matsumoto
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

10.  Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model.

Authors:  Marian L Kruzel; Jeffrey K Actor; Zsolt Radak; Attila Bacsi; Alfredo Saavedra-Molina; Istvan Boldogh
Journal:  Innate Immun       Date:  2009-09-01       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.